


Patent Claims

- Compounds of the general formula U-V-W, wherein U refers to the formula (I),



wherein

A is a optionally substituted 5- or 6-membered heteroarylen ring;

X is an oxygen atom, a sulfur atom, a group of the formula NR^{13} or $\text{CR}^{14}\text{R}^{15}$;

Y is an oxygen atom, a sulfur atom or a group of the formula NR^{16} and

the residues $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^6, \text{R}^7, \text{R}^8, \text{R}^9, \text{R}^{10}, \text{R}^{11}, \text{R}^{12}, \text{R}^{13}, \text{R}^{14}, \text{R}^{15}$ and R^{16} are independently from each other a hydrogen atom, a alkyl, alkenyl, alkynyl heteroalkyl, aryl, heteroaryl, cycloalkyl, alkylcycloalkyl, heteroalkylcycloalkyl, heterocycloalkyl, aralkyl or a heteroaralkyl group, or two of the groups are together part of a cycloalkyl or heterocycloalkyl ring system,

V is a linker and W a polymer or a biomolecule.

- Compounds according to claim 1, wherein the compound of the formula (I) is Tubulysin A.
- Compounds according to the claims 1 or 2, wherein the polymer is a polyethylene glycol (PEG).
- Compounds according to the claim 3, wherein the polyethylene glycol has a molecular weight of more than 30 kDa.
- Compounds according to the claims 1 or 2, wherein the biomolecule is an antibody.

6. Use of a bioconjugate according to one of the claims 1 to 5 for the treatment of cancer.